These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 33171124)

  • 1. NAD
    Lv H; Lv G; Chen C; Zong Q; Jiang G; Ye D; Cui X; He Y; Xiang W; Han Q; Tang L; Yang W; Wang H
    Cell Metab; 2021 Jan; 33(1):110-127.e5. PubMed ID: 33171124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity.
    Chen KC; Dhar T; Chen CR; Chen EC; Peng CC
    Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167106. PubMed ID: 38428685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma.
    Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L
    Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor.
    Yang Y; Li Z; Wang Y; Gao J; Meng Y; Wang S; Zhao X; Tang C; Yang W; Li Y; Bao J; Fan X; Tang J; Yang J; Wu C; Qin M; Wang L
    EMBO Mol Med; 2024 Apr; 16(4):885-903. PubMed ID: 38448544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
    Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
    Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
    Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
    EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
    Dai X; Bu X; Gao Y; Guo J; Hu J; Jiang C; Zhang Z; Xu K; Duan J; He S; Zhang J; Wan L; Liu T; Zhou X; Hung MC; Freeman GJ; Wei W
    Mol Cell; 2021 Jun; 81(11):2317-2331.e6. PubMed ID: 33909988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
    Zhao K; Zhang Q; Flanagan SA; Lang X; Jiang L; Parsels LA; Parsels JD; Zou W; Lawrence TS; Buisson R; Green MD; Morgan MA
    Mol Cancer Res; 2021 Sep; 19(9):1571-1582. PubMed ID: 34045311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity.
    Byun JK; Park M; Lee S; Yun JW; Lee J; Kim JS; Cho SJ; Jeon HJ; Lee IK; Choi YK; Park KG
    Mol Cell; 2020 Nov; 80(4):592-606.e8. PubMed ID: 33159855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
    Jia L; Xi Q; Wang H; Zhang Z; Liu H; Cheng Y; Guo X; Zhang J; Zhang Q; Zhang L; Xue Z; Li Y; Da Y; Zhao P; Zhang R
    Biochem Biophys Res Commun; 2017 Jun; 488(2):425-431. PubMed ID: 28511795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.
    Wei Y; Zhao Q; Gao Z; Lao XM; Lin WM; Chen DP; Mu M; Huang CX; Liu ZY; Li B; Zheng L; Kuang DM
    J Clin Invest; 2019 May; 129(8):3347-3360. PubMed ID: 31112529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
    Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.